Zobrazeno 1 - 10
of 23
pro vyhledávání: '"EJ Arenas"'
Publikováno v:
Cancer Research. 77:P5-07
Whether an aggressive phenotype is promoted through adaptation or resistance to target inhibition remains poorly understood. Here, complementary studies in human tumors, xenograft models and cell lines reveal transcriptional reprogramming that suppor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08f0c74cacc214c883bd91b40441aa05
https://doi.org/10.1158/1538-7445.sabcs16-p5-07-09
https://doi.org/10.1158/1538-7445.sabcs16-p5-07-09
Autor:
Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain., Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. alballop@gmail.com., Staniszewska AD; Oncology R&D, AstraZeneca, Cambridge, UK., Domènech-Vivó J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Programa de doctorat en Biomedicina, Universitat de Barcelona, Barcelona, Spain., García-Galea E; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Moles-Fernández A; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Pedretti F; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Domènech H; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Arenas EJ; Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Epigenetics Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Verdaguer H; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Calero-Nieto FJ; Oncology R&D, AstraZeneca, Cambridge, UK., Talbot S; Oncology R&D, AstraZeneca, Cambridge, UK., Tobalina L; Oncology R&D, AstraZeneca, Cambridge, UK., Leo E; Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Oncology R&D, AstraZeneca, Cambridge, UK., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Macarulla T; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Arribas J; Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Departament of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain.; Catalan Institution for Research and Advanced Studies, ICREA, Barcelona, Spain.; Cancer Research Program, The Hospital del Mar Research Institute, Barcelona, Spain., Díez O; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Gutiérrez-Enríquez S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Forment JV; Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, UK., Albertella M; Oncology R&D, AstraZeneca, Cambridge, UK., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. jbalmana@vhio.net.; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Autonomous University of Barcelona, Barcelona, Spain. jbalmana@vhio.net., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. vserra@vhio.net.
Publikováno v:
Genome medicine [Genome Med] 2024 Aug 26; Vol. 16 (1), pp. 107. Date of Electronic Publication: 2024 Aug 26.
Autor:
Yáñez-Bartolomé M; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serra-Camprubí Q; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arenas EJ; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Escorihuela M; Growth Factor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Castet F; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Fabregat-Franco C; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Querol J; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arribas J; Growth Factor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Cancer Research Program, Hospital de Mar Medical Research Institute (IMIM), Barcelona, Spain.; Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain., Peiró S; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Macarulla T; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. tmacarulla@vhio.net., Tian TV; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. tiantian@vhio.net.
Publikováno v:
Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2024; Vol. 2806, pp. 139-151.
Autor:
Adam-Artigues A; INCLIVA Biomedical Research Institute, Spain. Electronic address: anar4@alumni.uv.es., Arenas EJ; Josep Carreras Leukaemia Research Institute, Spain; Center for Biomedical Network Research on Cancer (CIBERONC), Spain. Electronic address: earenas@vhio.net., Arribas J; Center for Biomedical Network Research on Cancer (CIBERONC), Spain; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Spain; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Spain. Electronic address: jarribas@vhio.net., Prat A; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain; SOLTI Breast Cancer Research Group, Spain. Electronic address: ALPRAT@clinic.cat., Cejalvo JM; INCLIVA Biomedical Research Institute, Spain; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Spain; Department of Medical Oncology, Hospital Clínico Universitario de València, Spain. Electronic address: jmcejalvo@incliva.es.
Publikováno v:
Cancer treatment reviews [Cancer Treat Rev] 2023 Dec; Vol. 121, pp. 102639. Date of Electronic Publication: 2023 Oct 07.
Autor:
Saura C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Ortiz C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Matito J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Arenas EJ; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Suñol A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Martín Á; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Córdoba O; Servicio Obstetricia y Ginecología, Hospital Universitari Son Espases (HUSE), Palma, Spain.; Institut de Investigació de les Illes Balears (IdISBa), Palma, Spain.; Universitat de les Illes Balears (UIB), Palma, Spain., Martínez-Sabadell A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., García-Ruiz I; Obstetrics Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Miranda I; Radiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Morales-Comas C; Gynecology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Carrasco E; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Viaplana C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Peg V; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain., Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Bayó-Puxan N; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Gonzalez-Medina A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Miquel JM; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Gómez-Rey M; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Villacampa G; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Arévalo S; Obstetrics Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Espinosa-Bravo M; Gynecology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Balmaña J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Dienstmann R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Arribas J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.; Hospital del Mar Research Institute (HMRI), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Tabernero J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; University of Vic-Central University of Catalonia (UVic-UCC), Barcelona, VIC, Spain.; IOB Institute of Oncology, Quiron Group, Barcelona, Spain., Vivancos A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Sansó M; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.
Publikováno v:
Cancer discovery [Cancer Discov] 2023 Oct 05; Vol. 13 (10), pp. 2180-2191.
Autor:
Quintana Á; Breast Cancer Unit, Vall d'Hebrón Institute of Oncology, Barcelona, Spain., Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain., Bernadó C; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Navarro JF; Bioinformatics Department, Vall d'Hebrón Institute of Oncology, Barcelona, Spain., González J; Bioinformatics Department, Vall d'Hebrón Institute of Oncology, Barcelona, Spain., Esteve-Codina A; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain., Moliné T; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain., Marti M; Departament Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Barcelona, Spain., Curigliano G; European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy., Schmid P; Barts Cancer Institute, Queen Mary University London, London, United Kingdom., Peg V; Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.; Departamento de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain., Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.; Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain.; Catalan Institution for Research and Advanced Studies, (ICREA), Barcelona, Spain.; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain., Cortés J; Breast Cancer Unit, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.; International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Barcelona, Spain.; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2023 May 04; Vol. 14, pp. 1149747. Date of Electronic Publication: 2023 May 04 (Print Publication: 2023).
Autor:
Serra-Camprubí Q; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Verdaguer H; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Oliveros W; Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain., Lupión-Garcia N; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Llop-Guevara A; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Molina C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vila-Casadesús M; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Turpin A; Université de Lille, CNRS INSERM UMR9020-U1277, CANTHER Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.; Medical Oncology Department, CHRU Lille, Lille, France., Neuzillet C; Gastrointestinal Oncology, Medical Oncology Department, Curie Institute, Versailles St-Quentin-Paris Saclay University, Saint-Cloud, France., Frigola J; Clinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Querol J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Yáñez-Bartolomé M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Castet F; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Fabregat-Franco C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Escudero-Iriarte C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Escorihuela M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arenas EJ; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Bernadó-Morales C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Haro N; Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., Giles FJ; Developmental Therapeutics Consortium, Chicago, Illinois., Pozo ÓJ; Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., Miquel JM; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Nuciforo PG; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Melé M; Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain., Serra V; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arribas J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Tabernero J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Peiró S; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Macarulla T; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Tian TV; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jan 17; Vol. 29 (2), pp. 432-445.
Autor:
Duro-Sánchez S; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Bellaterra, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Nadal-Serrano M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Lalinde-Gutiérrez M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Bellaterra, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Arenas EJ; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Bernadó Morales C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Morancho B; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Escorihuela M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pérez-Ramos S; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Escrivá-de-Romaní S; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Gandullo-Sánchez L; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Pandiella A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Instituto de Biología Molecular y Celular del Cáncer, CSIC, Salamanca, Spain., Esteve-Codina A; NAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain., Rodilla V; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Dijcks FA; Byondis B.V., Nijmegen, the Netherlands., Dokter WHA; Byondis B.V., Nijmegen, the Netherlands., Cortés J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Saura C; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Arribas J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Publikováno v:
Cancer research [Cancer Res] 2022 Dec 16; Vol. 82 (24), pp. 4670-4679.
Autor:
Martínez-Sabadell A; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Bellaterra, 08193 Barcelona, Spain. Electronic address: amartinezs@vhio.net., Ovejero Romero P; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. Electronic address: povejero@vhio.net., Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain. Electronic address: jarribas@imim.es., Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain. Electronic address: earenas@vhio.net.
Publikováno v:
STAR protocols [STAR Protoc] 2022 Oct 26; Vol. 3 (4), pp. 101712. Date of Electronic Publication: 2022 Oct 26 (Print Publication: 2022).
Autor:
Martínez-Sabadell A; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, 08193 Bellaterra, Spain., Morancho B; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Rius Ruiz I; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain., Román Alonso M; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Ovejero Romero P; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Escorihuela M; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Chicote I; Translational Program, Stem Cells and Cancer Laboratory (VHIO), 08035 Barcelona, Spain., Palmer HG; Translational Program, Stem Cells and Cancer Laboratory (VHIO), 08035 Barcelona, Spain., Nonell L; Bioinformatic Unit (VHIO), 08035 Barcelona, Spain., Alemany-Chavarria M; Bioinformatic Unit (VHIO), 08035 Barcelona, Spain., Klein C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Zurich, Switzerland., Bacac M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Zurich, Switzerland., Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain. Electronic address: jarribas@imim.es., Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain. Electronic address: earenas@vhio.net.
Publikováno v:
Cell reports [Cell Rep] 2022 Oct 18; Vol. 41 (3), pp. 111430.